Bridging the Gap in Biosimilar Use And Uptake in Inflammatory Conditions

Originally published by our sister publication Specialty Pharmacy ContinuumJessica Fann, PharmDJulia Pate, PharmDDanielle Bryan, PharmDChelsea Renfro, PharmDVanderbilt Specialty PharmacyNashville, TennesseeWithin the last 5 years, the FDA has approved several key biosimilars for inflammatory conditions such as inflammatory bowel disease and rheumatologic disorders. Infliximab biosimilars entered the market in 2016 as IV infusions only and are billed through the medical benefit.1 In 2023 and 2025